目的 探討阿托伐他汀鈣片聯(lián)合小牛血清去蛋白注射液治療急性腦梗死的臨床療效。方法 選取2016年5月-2017年5月在駐馬店市中心醫(yī)院進行治療的急性腦梗死患者106例為研究對象，根據(jù)用藥的差別將所有患者分為對照組和治療組，每組各53例。對照組靜脈滴注小牛血清去蛋白注射液，20 mL加入到5%葡萄糖注射液250 mL中，1次/d。治療組在對照組基礎(chǔ)上睡前口服阿托伐他汀鈣片20 mg，1次/d。兩組患者均連續(xù)治療2周。觀察兩組的臨床療效，比較兩組的血清學(xué)指標(biāo)、血脂水平、美國國立衛(wèi)生研究院卒中量表（NIHSS）評分和日常生活能力量表（ADL）評分。結(jié)果 治療后，對照組和治療組的總有效率分別為81.13%、96.23%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組血清膠質(zhì)纖維酸性蛋白（GFAP）、心臟型脂肪酸結(jié)合蛋白（H-FABP）、血紅素氧合酶1（HO1）水平均顯著降低，轉(zhuǎn)化生長因子-β1（TGF-β1）和胰島素樣生長因子1（IGF-1）水平均顯著增高，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組治療后總膽固醇（TC）、三酰甘油（TG）、低密度脂蛋白膽固醇（LDL-C）水平均顯著降低，高密度脂蛋白膽固醇（HDL-C）水平均顯著升高，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對照組，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組NIHSS評分明顯降低，ADL評分顯著升高，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 阿托伐他汀鈣片聯(lián)合小牛血清去蛋白注射液治療急性腦梗死具有較好的臨床療效，可促進神經(jīng)功能恢復(fù)，改善日常生活能力，調(diào)節(jié)血脂水平和細(xì)胞因子水平，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of Atorvastatin Calcium Tablets combined and Deproteinised Calf Blood Serum Injection in treatment of acute cerebral infarction. Methods Patients (106 cases) with acute cerebral infarction in Zhumadian Central Hospital from June 2016 to May 2017 were enrolled in this study. According to the difference treatment plan, patients were divided into control and treatment groups, and each group had 53 cases. Patients in the control group were iv administered with Deproteinised Calf Blood Serum Injection, 20 mL added into 5% glucose solution 250 mL, once daily. Patients in the treatment group were po administered with Atorvastatin Calcium Tablets at bedtime on the basis of the control group, 20 mg/time, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and serological indexes, blood lipid levels NIHSS scores, and ADL scores in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.13% and 96.23%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of GFAP, H-FABP, and HO1 in two groups were significantly decreased, but the levels of TGF-β1 and IGF-1 in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05).After treatment, the levels of TC, TG, and LDL-C in two groups were significantly decreased, but the levels of HDL-C in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the NIHSS scores in two groups were significantly decreased, but the ADL scores in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Atorvastatin calcium combined and Deproteinised Calf Blood Serum Injection has clinical curative effect in treatment of acute cerebral infarction, can promote the recovery of neurological function, improve the ability of daily life, regulate blood lipid levels and cytokines levels, which has a certain clinical application value.